When combining intratumoral and peritumoral features, the performance metrics in the testing set for identifying HER2-low or HER2-positive cancers included an AUC of 0.846 (95 % CI: 0.740–0.934), sensitivity of 79.3 %, specificity of 72.7 %, and an accuracy of 77.3 % (Table 4, Fig. 4A-B). This evidence concerns the gene ERBB2 and cancer.